2 citations
,
February 2023 in “F&S Reports” Elagolix did not effectively treat polycystic ovary syndrome.
August 1994 in “Drugs & Therapy Perspectives” The document concludes that H2-antagonists and proton pump inhibitors are highly effective for ulcers, eradicating Helicobacter pylori is important to prevent recurrence, and misoprostol helps with NSAID-related ulcers.
December 2015 in “Vascular Pharmacology” Prasugrel is better than clopidogrel at preventing heart damage and improving blood flow in small heart vessels during heart artery procedures.
14 citations
,
March 2017 in “Brain research” Progesterone and its byproducts control a specific receptor in the brain independently of progesterone receptors, affecting conditions related to the menstrual cycle.
25 citations
,
July 2024 in “Frontiers in Pharmacology” Rimegepant causes more nausea and skin issues, while ubrogepant causes more muscle issues; personalized treatment is important.
July 2024 in “Journal of Investigative Dermatology” Inhibiting PDE8A may help treat hair loss by boosting fat cell growth and hair regeneration.
43 citations
,
August 2010 in “Expert Opinion on Investigational Drugs” Inhibitors of 11β-HSD1 show potential for treating type 2 diabetes but require more testing for safety and effectiveness.
80 citations
,
April 2017 in “Frontiers in Pharmacology” PDRN helps repair tissue and improve wound healing with a high safety profile.
4 citations
,
September 2025 in “Biomolecules” The effect of GLP-1 RAs on erectile function is unclear and needs more research.
9 citations
,
August 2014 in “European journal of ophthalmology” PGF2α receptors in human eyelids are found in specific parts of hair follicles, explaining eyelash changes with glaucoma treatment.
January 2020 in “Nihon Yakuri Gakkai nenkai yoshishu” Reducing 5α-reductase activity helps endometrial cells differentiate, aiding pregnancy.
42 citations
,
August 2012 in “Psychoneuroendocrinology” Finasteride reduces certain behaviors caused by D1-like receptor agonists but not by D2-like receptor agonists in mice.
1 citations
,
July 2022 in “Frontiers in Pharmacology” Dutasteride may help protect neurons and reduce inflammation in Parkinson's disease.
25 citations
,
January 2017 in “Steroids” Allopregnanolone increases growth and changes gene activity in human brain cancer cells.
52 citations
,
February 2006 in “Current pharmaceutical design” 5α-reductase inhibitors and alpha-1 adrenergic antagonists together effectively treat benign prostatic hyperplasia, with long-term benefits.
LGF injections may improve early Peyronie's disease by reducing penile curvature and plaque size.
October 2021 in “JAAD Case Reports” Topical glycopyrrolate lotion helped reduce excessive sweating from eating in a diabetic man.
1 citations
,
April 2013 in “The FASEB Journal” 3α‐OH‐DHP is essential for reducing nerve activity related to blood pressure control during pregnancy.
40 citations
,
July 2023 in “Clinical Pharmacology & Therapeutics” Targeted protein degraders show promise in treating cancer but need to target more diverse proteins.
44 citations
,
February 2009 in “Pain” Progesterone reduces spinal reflex activity by increasing certain GABA(A) receptor subtypes.
9 citations
,
January 2021 in “Acta Cirúrgica Brasileira” Dipotassium glycyrrhizinate helps wounds heal faster, especially in the early stages.
2 citations
,
January 2025 in “touchREVIEWS in Endocrinology” SGLT2 inhibitors may help manage PCOS symptoms effectively.
July 2023 in “Journal of Clinical Medicine” Tirzepatide might help manage PCOS in obese patients but needs more research to confirm safety and effectiveness.
54 citations
,
December 2007 in “Best Practice & Research Clinical Endocrinology & Metabolism” Targeting glucocorticoid action might help treat type-2 diabetes, but human trials are needed.
18 citations
,
November 2012 in “Current opinion in urology” Finasteride and dutasteride are equally effective and safe for treating benign prostatic hyperplasia.
February 2020 in “Bulletin of Experimental Biology and Medicine” Finasteride and GIZh-72 reduce inflammation, with GIZh-72 being more effective.
January 2019 in “Nihon Yakuri Gakkai nenkai yoshishu” Current treatments for lower urinary tract symptoms include α1-blockers, 5ARIs, PDE5 inhibitors, anticholinergic agents, and β3-adrenergic receptor agonists.
45 citations
,
April 2021 in “Current Treatment Options in Oncology” ADT for prostate cancer may harm the heart, but GnRH antagonists might be safer.
These medications for BPH have known risks and may have new side effects.
January 2009 in “Journal of Jilin Medical College” SDG helps reduce BPH effects in rats.